India’s beauty industry has spent the last few years moving far beyond creams, lipsticks, and skincare serums. Across metros and Tier-1 cities, aesthetic clinics offering Botox, dermal fillers, glutathione drips, anti-ageing injections, PRP therapy, and skin tightening procedures have rapidly entered the mainstream.
Social media influencers normalized these treatments, clinics aggressively marketed them, and younger consumers increasingly viewed cosmetic procedures as part of routine self-care.
Now, India’s drug regulator is stepping in.
In a public notice issued on May 18, 2026, the Central Drugs Standard Control Organisation (CDSCO) clarified that products supplied in injectable form do not qualify as cosmetics under Indian law. The regulator stated that cosmetics are intended to be “rubbed, poured, sprinkled or sprayed” on the human body and that no cosmetic product is permitted to be used as an injection by consumers, professionals, or aesthetic clinics.
The clarification may sound technical, but it signals a major shift for India’s fast-growing medical aesthetics ecosystem, where beauty procedures increasingly overlap with healthcare, pharmaceuticals, and wellness businesses.
Aesthetic Clinics Expanded Rapidly
The government’s intervention comes at a time when India’s aesthetics market is growing aggressively.
According to Grand View Research, India’s aesthetic medicine market generated revenue of approximately US$2.01 billion in 2024 and is projected to reach US$7.41 billion by 2033, growing at a compound annual growth rate of 15.6%.
Separately, IMARC Group estimated India’s medical aesthetics market at US$650.7 million in 2025, projecting it to reach US$1.33 billion by 2034.
While estimates vary because firms define the category differently, most industry reports point to the same trend: minimally invasive cosmetic procedures are becoming a major business segment in India.
This growth has been driven by rising disposable incomes, growing awareness of cosmetic procedures, medical tourism, and increasing demand for non-surgical treatments.
The shift is also cultural. Procedures once associated with celebrities or luxury dermatology clinics are now marketed to younger urban consumers through Instagram reels, influencer partnerships, and subscription-based aesthetic packages.
Regulators Draw A Line
The CDSCO clarification effectively draws a regulatory distinction between cosmetics and medical interventions.
Under India’s Drugs and Cosmetics Act, cosmetics are products applied externally to cleanse, beautify, or alter appearance. Injectable substances do not fall within that definition.
The regulator’s notice comes amid growing concerns over aesthetic procedures being promoted outside tightly supervised medical environments.
The Times of India reported that the government acted amid a rise in aesthetic and anti-ageing procedures being marketed through clinics and beauty establishments.
The Economic Times also linked the warning to growing global normalization of injectable products being used for aesthetic enhancement, including weight-loss drugs and anti-ageing therapies.
India Today reported that the clarification brings glutathione drips and anti-ageing injections under sharper scrutiny.
Importantly, the CDSCO notice does not create a new law banning medical aesthetic procedures altogether. Instead, it clarifies that injectable products cannot be categorized or marketed as cosmetics under existing legal definitions. Medical procedures involving approved drugs may still be performed under applicable medical regulations.
That distinction matters because aesthetic clinics often operate in a grey zone between beauty services and clinical healthcare.
Safety Concerns Intensify
Medical experts and dermatology associations have increasingly warned about unqualified operators performing cosmetic procedures.
Earlier this year, the Gujarat chapter of the Indian Association of Dermatologists, Venereologists and Leprologists launched an anti-quackery campaign targeting unsafe cosmetic procedures being conducted by untrained practitioners. The association flagged Botox injections, fillers, PRP therapy, laser treatments, and hair transplants being performed outside properly equipped medical facilities.
The organization stated that such procedures require specialized medical training and should only be conducted by qualified dermatologists or plastic surgeons.
Globally, regulators have also tightened scrutiny around cosmetic injectables. Reuters reported that British regulators had earlier warned injectable anti-wrinkle fillers could become “a crisis waiting to happen” without stronger oversight.
India now appears to be moving toward a stricter compliance framework as aesthetic medicine expands.
Business Models Could Change
The CDSCO clarification could significantly affect aesthetic clinics, wellness chains, cosmetic distributors, and influencer-led beauty businesses.
Injectable cosmetic procedures became commercially attractive because they offered high-margin recurring treatments compared with traditional dermatology consultations. Clinics increasingly bundled anti-ageing injections, skin brightening therapies, and contouring treatments into lifestyle packages.
Now businesses may face tighter oversight around advertising claims, practitioner qualifications, product sourcing, and treatment classification.
The shift also reflects a broader transformation within the beauty industry itself. International beauty companies are increasingly investing in medical aesthetics businesses globally. Reuters reported in 2025 that L’Oréal had taken stakes in clinics in China and North America to better understand the medical aesthetics market.
That trend highlights how cosmetic enhancement is evolving into a hybrid industry combining beauty, healthcare, pharmaceuticals, and wellness.
India’s regulator appears determined to ensure that this transition does not occur without clearer legal boundaries.
